Vir Biotechnology shares are trading higher after the company reported better-than-expected Q2 financial results.

Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M Estimate

Vir Biotechnology (NASDAQ:VIR) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.18 by 161.11 percent. This is a 158.75 percent increase over losses of $(0.80) per share from

Vir Biotechnology Appoints Brent Sabatini To Interim Principle Financial Officer Effective July 23 As The Company Begins Search For CFO

8-K filing — Vir Biotechnology, Inc. (VIR)

Filed: 2026-07-24 AccNo: 0001628280-26-049499 Size: 174 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers